P E Lønning

Summary

Affiliation: Haukeland University Hospital
Country: Norway

Publications

  1. ncbi request reprint Exemestane in breast cancer: current status and future directions
    P E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Clin Breast Cancer 1:S28-33. 2000
  2. ncbi request reprint Stepwise estrogen suppression manipulating the estrostat
    P E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, 5021, Bergen, Norway
    J Steroid Biochem Mol Biol 79:127-32. 2001
  3. ncbi request reprint Pharmacology and clinical experience with exemestane
    P E Lønning
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021, Bergen, Norway
    Expert Opin Investig Drugs 9:1897-905. 2000
  4. ncbi request reprint Clinico-pharmacological aspects of different hormone treatments
    P E Lønning
    Department of Oncology, Haukeland University Hospital, N 5021, Bergen, Norway
    Eur J Cancer 36:S81-2. 2000
  5. ncbi request reprint Is there a growing role for endocrine therapy in the treatment of breast cancer?
    P E Lønning
    Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Drugs 60:11-21. 2000
  6. ncbi request reprint Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
    P E Lønning
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Oncol 18:2234-44. 2000
  7. ncbi request reprint The potential for aromatase inhibition in breast cancer prevention
    P E Lønning
    Section of Oncology, Institute of Medicine, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 7:4423s-4428s; discussion 4411s-4412s. 2001
  8. ncbi request reprint Aromatase inhibitors and inactivators for breast cancer therapy
    Per E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Drugs Aging 19:277-98. 2002
  9. ncbi request reprint The role of aromatase inactivators in the treatment of breast cancer
    Per Eystein Lønning
    Department of Oncology, Haukeland Hospital, University of Bergen, N 5021 Bergen, Norway
    Int J Clin Oncol 7:265-70. 2002
  10. ncbi request reprint Aromatase inhibitors and inactivators for breast cancer treatment
    P E Lonning
    Department of Oncology, Institute of Medicine, Haukeland University Hospital, Bergen, Norway
    Eur J Cancer 38:S47-8. 2002

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Exemestane in breast cancer: current status and future directions
    P E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Clin Breast Cancer 1:S28-33. 2000
    ..The findings from these studies will determine the role of exemestane in early breast cancer and lay the foundation for assessing its potential role in breast cancer prevention...
  2. ncbi request reprint Stepwise estrogen suppression manipulating the estrostat
    P E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, 5021, Bergen, Norway
    J Steroid Biochem Mol Biol 79:127-32. 2001
    ..Future studies are warranted to explore alterations in gene expression and signaling mechanisms in response to different therapies in tumor tissue in vivo...
  3. ncbi request reprint Pharmacology and clinical experience with exemestane
    P E Lønning
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021, Bergen, Norway
    Expert Opin Investig Drugs 9:1897-905. 2000
    ..Sequential therapy with tamoxifen followed by exemestane is also being compared with tamoxifen monotherapy in the adjuvant setting. In addition, the drug may have potential for breast cancer prevention...
  4. ncbi request reprint Clinico-pharmacological aspects of different hormone treatments
    P E Lønning
    Department of Oncology, Haukeland University Hospital, N 5021, Bergen, Norway
    Eur J Cancer 36:S81-2. 2000
    ..Faslodex, the first representative of the so-called 'pure' oestrogen antagonists, has shown beneficial effects in patients resistant to tamoxifen [4]...
  5. ncbi request reprint Is there a growing role for endocrine therapy in the treatment of breast cancer?
    P E Lønning
    Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Drugs 60:11-21. 2000
    ....
  6. ncbi request reprint Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
    P E Lønning
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Oncol 18:2234-44. 2000
    ....
  7. ncbi request reprint The potential for aromatase inhibition in breast cancer prevention
    P E Lønning
    Section of Oncology, Institute of Medicine, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 7:4423s-4428s; discussion 4411s-4412s. 2001
    ..Results from ongoing studies examining the toxicity of aromatase inhibitors and inactivators in postmenopausal women will set the stage for future trials that explore them as preventive treatment options...
  8. ncbi request reprint Aromatase inhibitors and inactivators for breast cancer therapy
    Per E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Drugs Aging 19:277-98. 2002
    ..In addition, these novel compounds with lack of complete cross-resistance extend the scope of using sequential treatment options to maximise the duration of optimal endocrine therapy in metastatic breast cancer disease...
  9. ncbi request reprint The role of aromatase inactivators in the treatment of breast cancer
    Per Eystein Lønning
    Department of Oncology, Haukeland Hospital, University of Bergen, N 5021 Bergen, Norway
    Int J Clin Oncol 7:265-70. 2002
    ..The results from these studies will outline the potential role of exemestane in adjuvant treatment and, potentially, for breast-cancer prevention in postmenopausal women...
  10. ncbi request reprint Aromatase inhibitors and inactivators for breast cancer treatment
    P E Lonning
    Department of Oncology, Institute of Medicine, Haukeland University Hospital, Bergen, Norway
    Eur J Cancer 38:S47-8. 2002
  11. ncbi request reprint Microarrays in primary breast cancer--lessons from chemotherapy studies
    P E Lønning
    Section of Oncology, Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Endocr Relat Cancer 8:259-63. 2001
    ..This paper outlines our continuing studies exploring prognostic and, we hope, predictive factors in breast cancer therapy...
  12. ncbi request reprint Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy
    T Aas
    Department of Surgery, Haukeland University Hospital, N 5021 Bergen, Norway
    Eur J Cancer 39:438-46. 2003
    ..001 and P = 0.001, respectively). A key reason for this difference with respect to the factors predicting chemotherapy resistance could be due to the adjuvant use of tamoxifen in all patients harbouring ER-positive tumours...
  13. doi request reprint Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Jonas Lies vei 26, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 118:288-93. 2010
    ..Ongoing studies exploring tissue estrogen levels as well as gene expression profiles on therapy may further improve this important therapeutic area...
  14. ncbi request reprint Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study
    J Geisler
    Section of Oncology, Department of Medicine, Haukeland University Hospital, University of Bergen, NO 5021, Bergen, Norway
    Eur J Cancer 42:2968-75. 2006
    ..The bone marker values decreased, although a difference at 6 months of follow-up was still recorded, in particular for the markers of bone synthesis...
  15. ncbi request reprint Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients
    J Geisler
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    J Clin Endocrinol Metab 83:2687-93. 1998
    ..54 and 1.27 nmol/L during treatment with D-AG and DL-AG, respectively; P < 0.05)...
  16. pmc Aromatase inhibitors and their future role in post-menopausal women with early breast cancer
    P E Lønning
    Department of Therapeutic Oncology and Radiophysics, Haukeland University Hospital, Bergen, Norway
    Br J Cancer 78:12-5. 1998
    ..The results of these trials will help to determine whether anastrozole has any benefits over tamoxifen, the current treatment of choice in post-menopausal women with early breast cancer...
  17. doi request reprint Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Jonas Lies vei 26, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 117:31-41. 2009
    ..A possible explanation to our finding is increased ligand receptor binding capacity for E(2) in receptor positive tumours but alternative factors influencing intratumour estrogen disposition cannot be excluded...
  18. ncbi request reprint High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
    P E Lønning
    Department of Medicine, Haukeland University Hospital, Bergen, Norway
    Breast Cancer Res Treat 67:111-6. 2001
    ..Such treatment represents a valuable alternative to chemotherapy in selected patients...
  19. ncbi request reprint Aromatase inhibition for breast cancer treatment
    P E Lønning
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Acta Oncol 35:38-43. 1996
    ....
  20. ncbi request reprint Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy
    S I Helle
    Department of Medicine, Section of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    Eur J Cancer 41:694-701. 2005
    ..Similar response rates and time to progression in the treatment arms suggests moderate suppression of circulating IGF-I has no influence on clinical outcome...
  21. pmc The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 22:503-14. 2011
    ..This article examines the clinical data with aromatase inhibitors, following a brief summary of their pharmacology...
  22. ncbi request reprint Pharmacokinetics and metabolism of formestane in breast cancer patients
    P E Lønning
    Department of Oncology, Haukeland Hospital, University of Bergen, N 5021 Bergen, Norway
    J Steroid Biochem Mol Biol 77:39-47. 2001
    ..These exocons are formed by stereoselective 3-keto reduction, accompanied by reduction of the 4,5-enol function. The exocons do not inhibit human placental aromatase activity in vitro...
  23. ncbi request reprint Bone safety of aromatase inhibitors versus tamoxifen
    P E Lønning
    Department of Medicine, Section of Oncology, Haukeland University Hospital, Bergen, Norway
    Int J Gynecol Cancer 16:518-20. 2006
    ..While an increased fracture rate may have detrimental effects, evidence suggests that enhanced bone loss may be preventable through careful bone mineral density (BMD) assessment and treatment with bisphosphonates...
  24. ncbi request reprint Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 17:217-25. 2006
    ..Any difference in cost/utility between the strategies may be of importance to therapy selection...
  25. ncbi request reprint Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment
    H Haarstad
    Department of Oncology, Trondheim University Hospital, Norway
    Acta Oncol 37:365-8. 1998
    ..The response to droloxifene recorded in the present study is in accordance with the response rates to tamoxifen as first-line treatment in identical groups of patients...
  26. pmc Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer
    L A Akslen
    The Gade Institute, Section for Pathology, University of Bergen, Haukeland University Hospital, Bergen N 5021, Norway
    Br J Cancer 105:9-12. 2011
    ..Glomeruloid microvascular proliferation (GMP), a novel histology-based angiogenesis marker, has been associated with decreased survival in several human cancers...
  27. pmc Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
    M Hauglid Flågeng
    Institute of Medicine, University of Bergen, Bergen, Norway
    Br J Cancer 101:1253-60. 2009
    ..Characterisation of the molecular response to aromatase inhibitors in breast cancer tissue may provide important information regarding development of oestrogen hypersensitivity...
  28. ncbi request reprint Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis
    J Norum
    Department of Oncology, University Hospital of North Norway, Tromsø, Norway
    Acta Oncol 46:153-64. 2007
    ..Sensitivity analyses documented survival gain, price of trastuzumab, production gain and discount rate to be the major factors influencing cost-effectiveness ratio. Trastuzumab is indicated cost effective in Norway...
  29. ncbi request reprint Breast cancer prognostication and prediction in the postgenomic era
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, Norway
    Ann Oncol 18:1293-306. 2007
    ..On the basis of these findings, we suggest drug resistance may be explored on the basis of upfront biological hypotheses...
  30. ncbi request reprint Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
    P E Lønning
    Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    Eur J Cancer 45:527-35. 2009
    ..Neither do we know whether some tumours are more sensitive to particular drugs. This paper summarizes clinical findings up to now with respect to lack of cross-resistance and discuss potential mechanisms involved...
  31. pmc Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide
    P E Lønning
    Department of Therapeutic Oncology and Radiophysics, University of Bergen, Norway
    Br J Cancer 60:107-11. 1989
    ..The possibility that such effects might be partly responsible for the mechanism of action of aminoglutethimide in advanced breast cancer should be considered...
  32. doi request reprint RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer
    S Knappskog
    Department of Molecular Biology, University of Bergen, Bergen, Norway
    Ann Oncol 22:2208-15. 2011
    ....
  33. doi request reprint Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers
    P E Lønning
    1 Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway 2 Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Oncogene 32:5315-30. 2013
    ....
  34. ncbi request reprint Breast cancer prognostication and prediction: are we making progress?
    P E Lønning
    Institute of Medicine, University of Bergen, Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 18:viii3-7. 2007
    ..This article will focus on recent advances in prognostication and prediction, with emphasis on findings from gene expression profiling studies...
  35. ncbi request reprint Aromatase inhibitors in breast cancer
    P E Lønning
    Section of Oncology, Institute of Medicine, Haukeland University Hospital, University of Bergen, 5021 Bergen, Norway
    Endocr Relat Cancer 11:179-89. 2004
    ..Interesting findings such as the lack of cross-resistance between steroidal and non-steroidal compounds should be further explored, as this may add additional information to our understanding of breast cancer biology...
  36. pmc Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
    S E Monstad
    Department of Neurology, Haukeland University Hospital, Bergen, Norway
    Clin Exp Immunol 144:53-8. 2006
    ..The results show that the prevalence of Yo antibodies is low in ovarian and breast cancer. Yo antibodies may be associated with advanced cancer, but less often with PNS...
  37. ncbi request reprint The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy
    S I Helle
    Department of Oncology, Haukeland University Hospital, N 5021 Bergen, Norway
    J Clin Endocrinol Metab 86:227-33. 2001
    ..Our results reveal several alterations in the IGF system during HIV infection with decreased IGF-II levels, increased concentration of IGFBP-2, and an increased IGFBP-3 protease activity in advanced disease...
  38. ncbi request reprint Treatment of early breast cancer with conservation of the breast. A review
    P E Lønning
    Department of Oncology and Radiophysics, Haukeland Sykehus, Bergen, Norway
    Acta Oncol 30:779-92. 1991
    ..The need for radiotherapy after local excision for small intraductal (ductal carcinoma in situ) cancers is being addressed in ongoing trials...
  39. doi request reprint Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia
    N Anensen
    Hematology Section, Institute of Medicine, University of Bergen, Bergen, Norway
    Oncogene 31:1533-45. 2012
    ..In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms β and γ expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication...
  40. pmc The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling
    M Chekenya
    Norlux Neuro Oncology Group, Department of Biomedicine, University of Bergen, Bergen, Norway
    Oncogene 27:5182-94. 2008
    ..Thus, as a novel regulator of the antiapoptotic response, NG2/MPG may represent an effective therapeutic target in several cancer subtypes...